Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials - The Lancet
Empagliflozin reduces hospitalization and mortality in HF with preserved EF, NEJM.
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
CMSJ :: CardioMetabolic Syndrome Journal
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER | Nature Medicine
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population - ScienceDirect
Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke
SGLT2 inhibitors now 'pillars of care' for HF
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial | JACC: Heart Failure
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
DELIVER Trial Scores a Win for Dapagliflozin in HFpEF | tctmd.com
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction - American Journal of
University of Glasgow - Schools - School of Cardiovascular & Metabolic Health - News - March - May 2020 - DAPA-HF & PARAGON
PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF | tctmd.com
Pooled analysis DAPAHF+DELIVER
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER | Nature Medicine
FARXIGA Met Primary Endpoint in DELIVER Phase III Trial | DAIC
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial - Solomon - 2021 - European Journal of Heart Failure - Wiley Online Library
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? | SpringerLink
